Optimer Pharmaceuticals' (NASDAQ:OPTR) Fidaxomicin Should Drive Stock in 2011

With the expected approval of their lead drug fidaxomicin expected in 2011, Optimer Pharmaceuticals (NASDAQ:OPTR) should get a big boost next year after a U.S. and European Union go ahead.

Canaccord said, "We continue to believe Optimer’s lead drug, fidaxomicin (fidaxo) for the treatment of Clostridium difficile infection (CDI), offers a strong value proposition. We believe that approval of the drug in the US and EU next year will drive significant upside in the stock."

Optimer closed at $9.48 Friday, gaining $0.38, or 4.18 percent. Canaccord has a hefty price target on them of $18, and maintains their "Buy" rating on them.